🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

Fauci apologizes for casting doubt over UK's approval of Pfizer vaccine

Published 2020-12-03, 05:56 p/m
© Reuters. FILE PHOTO: Fauci testifies before coronavirus panel
PFE
-

By Estelle Shirbon

LONDON (Reuters) - Top U.S. infectious diseases expert Anthony Fauci apologized on Thursday for casting doubt on the rigor of the British regulators who approved the Pfizer Inc (NYSE:PFE) vaccine against COVID-19, saying he had faith in the quality of their work.

Britain announced the approval of the vaccine on Wednesday, with the Medicines and Healthcare products Regulatory Agency (MHRA) saying it had rigorously assessed the vaccine data and had cut no corners.

It gave the UK the jump in the race to begin mass inoculation against a virus that has killed nearly 1.5 million people globally and hammered the world economy. U.S. and European Union regulators are sifting through the same Pfizer vaccine trial data, but have yet to give their approval.

In a CBS interview on Thursday, Fauci suggested the British regulators had failed to scrutinize the data carefully enough and had waved the vaccine through - comments that were prominently reported on the main British TV news channels.

He later gave an interview to the BBC in which he said his earlier comments had come out wrong.

"There really has been a misunderstanding, and for that I'm sorry, and I apologize for that," he said. "I do have great faith in both the scientific community and the regulatory community in the UK," Fauci said.

"I did not mean to apply any sloppiness (to the UK regulatory process), even though it came out that way," he added.

Fauci said the point he had been trying to make was that in the U.S. context, with widespread vaccine scepticism, it would not have been appropriate to conduct the process in the same way and at the same speed as what happened in Britain.

"If we had for example approved it yesterday or tomorrow, there likely would have been pushback on an already scrutinising society," he said.

"You know, at the end of the day, it's going to be safe, it's going to be effective, the people in the UK are going to receive it and they're going to do really well, and the people in the United States are going to receive it and we're going to do pretty well," Fauci said.

In response to his earlier criticism, the MHRA issued a statement saying it had "rigorously assessed the data in the shortest time possible without compromising the thoroughness of our review".

The regulator also said its emergency approval had allowed "some stages of this process to happen in parallel to condense the time needed, but it does not mean steps and the expected standards of safety, quality and effectiveness have been bypassed".

Fauci is the most high-profile member of the White House coronavirus task force and has often clashed with President Donald Trump on how to protect Americans from the virus, which has caused about 273,000 U.S. deaths.

© Reuters. FILE PHOTO: Fauci testifies before coronavirus panel

President-elect Joe Biden said on Thursday he had asked Fauci to be the chief medical adviser on his COVID-19 team when he takes office on Jan. 20. [nW1N2HQ0GG]

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.